David Adson CV

Untitled Document

David Eric Adson, M.D. Curriculum Vitae Office Address: MAPS Applied Research Center 7450 France Avenue South, Suite 265 Edina, MN 55345 952-937-9000 www.mapsresearch.com Undergraduate Education: 1971-1974

The Colorado College University of Minnesota, College of Biological Sciences B.S. in Biology, Summa Cum Laude

Postgraduate Training and Medical Residency: 1976-1980

University of Minnesota, Minneapolis, School of Medicine M.D., Alpha Omega Alpha

1980-1981

Intern in Department of Surgery, Emory University Affiliated Hospitals, Atlanta, Georgia

1982-1983

Department of Orthopedic Surgery, Emory University, Atlanta, Georgia

1993-1996

Department of Psychiatry, University of Minnesota

Academic/Professional Appointments: 1984-1988

Clinical Assistant Professor of Family Practice, University of Minnesota, Minneapolis, Minnesota

1996-1998

Instructor in Psychiatry, University of Minnesota, Minneapolis, Minnesota

1998- present

Assistant Professor, University of Minnesota, Department of Psychiatry, Minneapolis, Minnesota

1999-present

Clinical Assistant Professor, University of Minnesota, Department of Pharmacology, Minneapolis, Minnesota

2004-2009

Associate Professor, University of Minnesota, Department of Psychiatry

2009-present

Adjunct Associate Professor, U of MN Department of Psychiatry

Certification and Licensure: American Board of Medical Examiners Board Certified in Psychiatry: Certificate #49096 State of Minnesota; #27588 State of Georgia; #22706, not active U.S. DEA certification #AA1097989 Employment: 1981-1982

Emergency Department Physician, Crawford Long Memorial Hospital, Atlanta, Georgia

The world’s largest digital library

Try Scribd FREE for 30 days to access over 125 million titles without ads or interruptions! Start Free Trial Cancel Anytime.





Untitled Document 1983-1984

Emergency Department Physician at Eitel Hospital and Golden Valley Medical Center, Minneapolis, Minnesota

1984-1988

Family Practice; Tyrol Medical Clinic, Golden Valley, Minnesota

1987-1992

Consultant to M-T (Med. Tech.) Venture Capital Group, Minneapolis, Minnesota

1988

Wayzata Family Practice, Wayzata, Minnesota

1989-1993

Staff Physician, Phalen Clinic, Columbia Heights, Minnesota

1993-1996

Resident Physician in Psychiatry, Minneapolis, Minnesota

1997-ongoing

Have served, or am currently serving on the speakers bureau for Astra Zeneca, Bristol Myers Squibb, Glaxo Smith Kline, Forest Labs, Organon, and Pfizer pharmaceuticals

1999-2001

Psychiatric Consultant, Fairview Northland Clinic, Princeton, Minnesota

2001-ongoing

Psychiatric Consultant, Family Life Center, Coon Rapids, Minnesota

2006-2008

Clinical Lead Minnesota Department of Human Services - Medicaid Mental Health Pharmacy Management Project

2009-ongoing

Principal Investigator, MAPS Applied Research Center, Edina, Minnesota

Honoraries and Professional Societies: Alpha Omega Alpha; The Honor Medical Society American Psychiatric Association American Association for the Advancement of Science The International Society of Affective Disorders Society of Biological Psychiatry Ad Hoc Review for: The Annals of Pharmacotherapy The Journal of Psychopharmacology The Journal of Laboratory and Clinical Medicine CNS Drugs: Adis Drug Profile Committee and Administrative Service: 1994-2005

Member, IRB (Institutional Review Board); Human Subjects Committee, University of Minnesota





Untitled Document Professor of Clinical Psychopharmacology 1999-2008

Member AHC Conflict Review and Management Committee

1999-2007

Vice-Chair, Department of Psychiatry Research Committee

1999-2007

Member, Department of Psychiatry Research Council

1999-2000

Member, Chemical Abuse and Recovery Evaluation (CARE) Advisory Committee established by the Corrections Commissioner to evaluate chemical dependency programming within the Minnesota Department of Corrections

Autumn, 2002

Member, Mental Health Task Force (working with Minnesota Council of Health Plans). Task force commissioned by the Attorney General

2002-present

Director, Ambulatory Research Center, University of MN Department of Psychiatry

Instructional Experience: Full time clinical duties include: Supervision and training of 3rd and 4th year medical students, PharmD students, and psychiatry residents PGY1-4. 1996-1997

AdPy 5121 (College of Physical Therapy); "Somatoform and Dissociative Disorders, Eating Disorders"

1996- present

Since initial appointment to faculty: inpatient service for two years; transition to outpatient clinic for several years; appointment to

consult liaison

service; currently with mix of outpatient clinic and consult liaison service 1996-present

AdPy 5500 (Medical School) "Psychopharmacology"; provide overview of psychopharmacology to 3rd and 4th year medical students during their 6 week psychiatry rotation

1997-present

AdPy 5500 (Medical School) "Clinical Application of Antidepressants" (as above, for 3rd and 4th year medical students)

1998-1999

AdPy 5121 (Medical School); "Dementia and Delirium, Somatoform Disorders"

1999-present

Course Committee Member, Year 2 Psyche Psyche Course: Course: Psychopathology I, Physiological Treatments I: "Treatment and diagnosis of psychotic disorders other than schizophrenia"

2003

Psychopathology III, Winter 2003 (residents): "Psychological Factors Affecting Medical Conditions"

2006-present

Psychopharmacology Course for G3s; Kis of SGAs and ADs, review review of MAOIs, rating scales in clinical practice

Peer- Reviewed Publications: McLaughlin EG, McLaughlin DJ & Adson DE: Developmental anatomy of a dimitic basidiomycete, Pterula sp.; Canadian Journal of Botany; 56,3:





Untitled Document

Adson DE, Crow SJ, Meller WH, & Magraw, RM: Potential drug-drug interactions on a tertiary-care tertiary-care hospital consult liaison psychiatry service. Psychosomatics, 39, 4: 360-5 1998 Kim SW, Grant JE, & Adson DE: Double-Blind Naltrexone and Placebo Comparison Study in the Treatment of Pathological Gambling. Biological Psychiatry, 49: 11, 2001 Kim SW, Grant JE, Adson DE, & Remmel R: A Possible Naltrexone and Nonsteroidal Analgesics Interaction. Journal of Clinical Psychopharmacology, 21: 632-634, 2001 Data collection, collection, revision of manuscript Adson DE & Kotlyar M: A Probable Probable Interaction Between an Oral Contraceptive and the the Antidepressant Nefazodone: A Case Report. Journal of Clinical Psychopharmacology, 21,:618-619, 2001 Adson DE, Erickson-Birkedahl SL, & Kotlyar Kotlyar M: Case Report; An Unusual Presentation of of Sertraline and Trazodone Overdose. The Annals of Pharmacotherapy, 35: 1375-1377, 2001 Kim SW, Grant JE, Adson DE, Shin YC,& YC,& Zaninelli R: A double-blind, placebo-controlled study of the efficacy and safety of paroxetine in the treatment of pathological gambling disorder. Journal of Clinical Psychiatry, 63,6: 501-507, 2002 Adson DE & Kotlyar M: Premature Ejaculation Associated With Citalopram Withdrawal. The Annals of Pharmacotherapy, 37: 1804-1806, 2003 Literature review and manuscript preparation Adson DE, Kushner MG, Eiben KM, & Schulz Schulz C: Preliminary Experience with Adjunctive Quetiapine in Patients on Selective Serotonin Reuptake Inhibitors. Depression and Anxiety, 19: 121-126, 2004 Kotlyar M, Brauer L, Tracy TS, TS, Hatsukami DK, Harris J, Bronars CA, Adson DA. Inhibition of CYP2D6 activity by bupropion. Journal of Clinical Psychopharmacology, 25:225-29, 2005 Adson, DE, Kushner MG, Fahnhorst TA: Treatment of Residual Anxiety Symptoms with Adjunctive Aripiprazole in Depressed Patients Taking Selective Serotonin Serotonin Reuptake Inhibitors. Journal of Affective Disorders, Disorders, 86: 99-104, 2005 Kotlyar M, Dysken M, Adson DE. Update on drug-induced depression in the elderly. Am J Geriatr Pharmacother, 4(1):288-300, March 2006. Kotlyar M, Brauer LH, al'Absi M, Adson DE, Robiner W, Thuras P; Harris J, Finocchi ME; Bronars CA, Candell S, Hatsukami DK. Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal. Pharmacol Biochem Behav, 2006; 83:370-379. Kushner MG, Kim SW, Donahue C, Thuras P, Adson D, Kotlyar M, McCabe J, Peterson J, Foa EB. D-Cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biological Psychiatry 2007 Oct Oct 15;62(8):835-8 . Pardo JV, Sheikh SA, Kuskowski MA, Surerus-Johnson C, Hagen MC, Lee JT, Rittberg BR, Adson DE. Weight loss during chronic, cervical vagus nerve stimulation in depressed patients with obesity: an observation. International Journal of Obesity, June 12, 2007, 1-4. Von Ruden AE, Adson DE, Kotlyar M, Effect of selective serotonin reuptake inhibitors on cardiovascular morbidity and mortality. J Cardiovasc Pharmacol Ther. Mar 2008 13(1):32-40. Kotlyar M, Donahue C, Thuras P, Kushner MG, O'Gorman N, Smith FA, Adson DE. Physiological response to a speech stressor presented in a virtual reality environment. Psychophsiology, Sept 4, 2008. Pardo JV, Sheikh SA, Schwindt GC, Lee JT, Kuskowski MA, Surerus C, Lewis SM, SM, Abuzzahab FS, Adson DE, Rittberg BR. Chronic vagus nerve stimulation for treatment-resistant depression decreases resting ventromedial prefrontal glucose glucose metabolism. Neuroimage, Aug. 15, 2008 42(2):879-89. Donahue CB, Kushner MG, Thuras PD, Murphy TG, Van Demark JB, Adson DE. Effect of Quetiapine versus Placebo on Response to Two Virtual





Untitled Document Spectrums, 2009 14(4): 197-206 Books and Book Chapters: Mitchell JE, Pomeroy C & Adson DE: Managing medical complications of eating disorders (book chapter) Handbook of Psychotherapy of Eating Disorders; Garner D, Garfinkel P; Guilford Press NY, April 1997 Mitchell JE, Crosby R, Wonderlich S, & Adson DE: Elements of Clinical Psychiatric Research (Book); APA press; May 2000. Other Publications: Adson DE: Seasonal Affective Disorder; Minnesota Health Care News, October 2003 and Minnesota Physician Jan. 2004 Adson DE: Considering Long-Term Outcome and Tolerabil ity in the Treatment of Bipolar Disorder, Current Psychosis and Therapeutics Reports, 2: 121-127, 2004 Pardo JV, Sheikh SA, Schwindt G, Lee JT, Surerus-Johnson C, Pardo PJ, McCarten JR, Kushowski MA, Dysken MW, Abuzzahab F, Rittberg BR, Adson DE. Functional neuroimaging in treatment - resistant depression. Depression: Mind and Body, 2007; 3(2):57-70. Grants/Research: NIH/Foundation: Principal Investigator (with Mitchell JE and Crow SJ); "Naltrexone in Binge Eating Disorder", March 1995-1997 $24,600 (Direct Cost) Dept. Funded Co-Investigator (Crow SJ as PI); "Stepped Care vs. Best Available Care for Bulimia Nervosa", NIH RO1 grant, awarded 1999-ongoing $1,303,765 (Direct Cost) Co-Investigator (with Kotlyar M); "Effect of Paroxetine on Physiological Response to Mental Stress" 2000-2003 $17,000 (Direct Cost) University of Minnesota Graduate School Co-Investigator (with Kotlyar M); "Paroxetine Effects on Cardiovascular Response to Mental Stress in Patients with Stable Angina"2001-ongoing $80,000 (Direct Cost) AHA Co-Investigator (with Kotlyar M, Hatsukami D); Effects of Desipramine and Nicotine Patch on Smoking Behavior" 2002 NIMH Co-Investigator (with Kotlyar M, Kushner M, al'Absi M, Hatsukami D); "Effects of Zyban and Cognitive Behavioral Therapy on Stress Reactivity and Smoking Withdrawal Symptoms" 2001-ongoing $168,852 (Direct Cost) AHC/Fairview grant Co-Investigator (with Kotlyar M); Effect of Buproprion on the Cytochrome P450 Drug Metabolizing Enzyme MMF 2004-2006 Co-Investigator (with Kushner, MG); "CBT Treatment of Anxiety Disorder in Comorbid Alcoholics. NIAAA. 9/05 - 8/31/2010 $1,250,000 (Direct). Co-Investigator (with Kushner, MG, Donahue, C); "D-Cycloserine Augmentation of Behavioral Therapy for Smoking Cessation" 2 006-2008 MMF grant $14,000 Investigator initiated: Principal Investigator (with Clayton PJ); "Pilot Study of Remeron TM (mirtazapine) in Depressed Patients Greater than 70 Years of Age", February 1997 - October 1997 $29,800 (Direct Cost) Co-Investigator (with Kim SW); "An Open Study of Naltrexone in the Treatment of Pathological Gambling Disorder", September 1997 - December 1997 Co-Investigator (with Kim SW); "Double-Blind Study of Naltrexone and Placebo Treatment of Pathological Gambling Disorder", December 1997 November 1999 $46,412 (Direct Cost)





Untitled Document Principal Investigator Investigator (with Brown E); "Aripiprazole as an Adjunctive Treatment for

Persistent Anxiety in Those Receiving Treatment with an

SSRI" 2003- $39,500 (direct cost). Principal Investigator; _The use of Quetiapine in the Treatment of Social Phobia Effect on Cue Reactivity in Response to Virtual Reality Public Speaking Environment 08/30/06- 08/27/07, $113,000. Selected industry sponsored multi-center trials: Co-Investigator (with Rittberg BR, Kim SW, Meller WH); "A Multicenter, Double-Blind, Placebo-Controlled, Flexible Dose Evaluation of the Safety and Efficacy of LAMICTAL (Lamotrigine) in the Treatment of Major Depressive Episode in Patients with Bipolar Disorder" (SCAA2110). September 1997 - July 1998 $125,000 (Direct Cost) Principal Investigator (with Clayton PJ, Rittberg BR) "An Open Label Evaluation of the Efficacy, Safety, and Dosing of Citalopram in Outpatients with Depression" (CIT-MID #97-06-000) July 1998 - September 1998 $20,600 (Direct Cost) Principal Investigator (with Rittberg BR, Hermann SA, Sheikh SA); "Olanzapine Plus Fluoxetine Combination Therapy in Treatment-Resistant Depression: A Dose Ranging Study", December 1999 -2001 $175,000 (Direct (Direct Cost) Co-Investigator (with Rittberg BR) "A Multicenter, Pivotal, Safety and Efficacy Study of the NeuroCybernetic Prosthesis (NCP®) System in Patients with Depression" Depression" Cyberonics, Inc. Protocol D-02; May 2000-ongoing $341,500 (Direct Cost) Co-Investigator (with Rittberg BR, Hermann SA); "A Long Term Prospective, Multicenter Study to Compare the Clinical Quality of Life, and Health Care Utilization of the NCP System to the Standard of Care Treatment with Depression (Cyberonics D-04); May 2000-ongoing Principal Investigator (with Meller WH) "A Randomized, Double-Blind, Parallel Group, Placebo Controlled Study Evaluating the Efficacy and Safety of Three Doses of SB-659746-A (5 mg, 10 mg, and 20 mg/day) Versus Placebo in Patients with Major Depressive Disorder" SB-659746-A/002, September 2001- June 2003 $94,000 (Direct Cost) Principal Investigator (with Meller WH) "An Double-Blind Study of the Safety and Efficacy of Lu 26-054 in Patients with Generalized Anxiety Disorder" Forest Laboratories Laboratories Protocol SCT-MD-06; June 2001- May 2003 $79,000 (Direct Cost) Principal Investigator "An Open-Label Extension Study of the Safety and Efficacy of Lu 26-054 in Patients with Generalized Anxiety Disorder" Forest Laboratories Protocol SCT-MD-17; November 2001- May 2 003 $20,700 (Direct Cost) Co-Investigator (with Willenbring M as PI) "A Phase III, Multi-Center, Randomized, Double Blind, Placebo Controlled Study of the Efficacy and Safety of Medisorb Naltrexone in Alcohol Dependent Adults" ALK21-003, March 2002 - present $142,000 (Direct Cost) Principal Investigator "A Multicenter, Double-Blind Randomized, Placebo-Controlled Comparison of the Effects on Sexual Functioning of ExtendedRelease Bupropion Hydrochloride (300-400mg) and Escitalopram (10-20mg) in Outpatients with Moderate to Severe Major Depression over an Eight-Week Treatment Period" January 2003 - Present $179,000 (Direct Cost) Principal Investigator "A 7 Month, Multicenter, Parallel, Double-Blind, Placebo-Controlled Comparison of 150-300 mg/day of Extended-Release Bupropion Hydrochloride and Placebo for the Prevention of Seasonal Depressive Episodes in Subjects with a History of Seasonal Affective Disorder Followed by an 8 week Observational Follow-up Follow-up Phase." October 2003-- Present $104,500 (Direct Cost) Cost) Principal Investigator; A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study of the Safety of Aripiprazole as Adjunctive Therapy in the Therapy in the Treatment of Patients With Major Depressive Disorder May 2005-ongoing likely through 2006 $320,000 direct Principal Investigator; A Multi-Center, Double-Blind, Randomized-Withdrawal, Parallel-Group, Placebo-Controlled, Phase III Study Study of the Efficacy and Safety of Quetiapine Fumarate Sustained Release (Seroquel SR) as Monotherapy in the Maintenance Treatment of Patients with Major Depressive Disorder Following an Open-Label Stabilization Period (Amethyst Study); April 2006-ongoing $215,420 direct







Untitled Document Selected Presentations: Summer 1993

Invited Lecturer; "The Sociology of Death" (Soc 5956)

November 1993

Psychiatry Grand Rounds, VA medical center; "Suicide: an overview"

Winter 1994

Invited lecturer; "The Sociology of AIDS" (Soc 5960)

April 1994

Psychiatry Grand Rounds, University of MN, Case Presentation,

Minneapolis, MN November 1994 June 1995 July 1996 1996

Tuesday Morning Departmental conference; "Lithium and the Kidney" Tuesday Noon Journal club; "Therapies for binge eating disorder"

Invited Lecturer Lecturer "Sociology of Mental Mental Illness" (Soc. 5150); history of psychopharmacology

Eating disorders in China; panel discussant; "Culture and Prevalence of Eating Disorders", Disorders", American Psychiatric Association Annual

Meeting, New York, NY September 1996 November 1997 October 1999

Medical Resident's Noon Conference: "Anxiety Disorders" "Mirtazapine Treatment in the Elderly", Remeron Expert Meeting, Charleston, Charleston, SC Invited Lecturer: "Current Issues in the Treatment of Depression". Update on Assessing

Depression. Menninger Continuing Education, Bloomington, MN July 1999

Medical Resident's Noon Conference: "Treatment of Depression"

February 2000

Grand Rounds Presentation: "How Are the Selective Serotonin Serotonin Reuptake Inhibitors Different?" Altru Health System, Grand Grand Forks,

ND February 2000

Grand Rounds Presentation: Presentation: "An Unusual Case of Serotonin Syndrome" (faculty discussant for a case presented by Jill Nasby, MD),

University of Minnesota, Minneapolis, MN July 2000

Grand Rounds Presentation: Presentation: "Anxiety Disorders: An Overview". Department of Family Family Practice, Practice, Mayo Foundation, Rochester, MN

October 2000

Annual Psychiatry Review (CME program): Mood Disorders: "Serotonin Syndrome and SSRIs", University of Minnesota,

Minneapolis, MN March 2001

E.N.T. Residents evening lecture; "A Practical Approach to Treating Anxiety and Depression"





Untitled Document

April 2003

Presentation to Department of Medicine Noon Conference: "Impact of Mood and Anxiety Disorders in the Medically Ill", University of

MN June 2003

HealthEast CME program: "Pharmaceutical Approaches to Anxiety and Depression"

September 2003

Boynton Health Health Center CME program: "Treatment of of Anxiety and Depression: A Focus on Drug Interactions"

November 2003

Investigator Sponsored Studies Consultants Meeting. "Quetiapine as an Adjunctive Therapy for Persistent Anxiety in Those

Patients Receiving an SSRI, Aventura, FL September 2003 October 2003

University of MN Dept. of Psychiatry 4th Annual CME Review: "Treatment of Depression with CoMorbid Anxiety Disorders

28th Annual MAPA Fall CME conference: "Impact of Depression and Anxiety on Medical Illness"

February 2004

CME activity (sponsored by AstraZeneca): Treatment Treatment Advances in the Spectrum of Mood Disorders. Disorders. ""Bipolar Affective Disorder;

Prevalence and Diagnostic Issues", Bloomington, MN Sept. 19-20, 2005

Course director director and moderator for 6th annual psychiatry review: "An Entertaining and Eclectic Elucidation of Psychiatric

Erudition", Minneapolis, MN 2006

American Psychiatric Association Meeting Symposium: The Use of SGAs in depression depression and anxiety.

Sept. 25-26, 2006 June 2007

Course director and moderator for 7th annual psychiatry review: review: "The Impulsive-Compulsive Spectrum", Minneapolis, MN

Presentation to U of M AHC Office of Clinical Research - LifeScience Alley Breakthrough Series. "Specific Disease Sates - Clinical

Applications of Neuromodulation". Minneapolis, MN June 2007

Grand Rounds Presentation: Presentation: "Case Presentation: Post Infectious Brain Disorder (PANDAS?)". The University of Minnesota Minnesota Department

of Psychiatry Selected Abstracts: Kim SW, Grant JE, Adson DE, Shin YC, Toth JA: "A Double-Blind, Placebo-Controlled Study of Naltrexone in the Treatment of Pathological Gambling Disorder" (oral presentation). New Research Program and Abstracts, 153rd Annual Meeting of the American Psychiatric Association, Chicago, Chicago, IL 2000 Kim SW, Grant JE, Shin YC, Toth JA, Adson DE, Zaninelli R: "A Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of Paroxetine Paroxetine in the Treatment of Pathological Gambling Disorder" (poster). (poster). New Research Program and Abstracts, 153rd Annual Meeting of the the American Psychiatric Association, Chicago, IL 2000 Kim SW, Grant JE, Adson DE, Shin YC, YC, Toth JA: "A Double-Blind, Placebo-Controlled





Untitled Document Kotlyar M, Brauer LH, al'Absi M, Adson DE, Robiner W, Thuras P; Harris J, Finocchi ME; Bronars CA, Candell S, Hatsukami DK. Effect of bupropion on physiological measures of stress in smokers during nicotine withdrawal (abstract). SRNT Annual Meeting, Orlando, FL (February 2006). Presented as Encore Presentation at CPNP Annual Meeting, Baltimore, MD (April 2006) El-Khalili N, Banov M, Bortnick B, Adson D, Datto C, Raines S, Earley W, Brecher M . Efficacy and tolerability of of extended release quetiapine fumarate (Quetiapine XR) monotherapy in major depressive disorder (MDD): a randomized, placebo-controlled clinical trial (Study 003). Presented as poster at Society of Biological Society (May 2008) Berman RM, Fava M, Thase ME, Trivedi MH, Swanink R, McQuade RD, Carson WH, Adson D, Taylor L, Hazel J, Marcus RN. The third consecutive, positive, double-blind, placebo-controlled trial of apripiprazole augmentation in the treatment treatment of major depression (Study CN138-165). Presented as poster at American College of Neuropsychoharmacology 47th Annual Meeting (Dec. 2008)

David Adson CV

Recommend Documents